PAM
SLNO

Panagora Asset Management’s Soleno Therapeutics SLNO Stock Holding History

Panagora Asset Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-363
Closed -$15K – 2617
2019
Q2 		$15K Sell
363
-515
-59% -$17.8K ﹤0.01% 2334
2019
Q1 		$27K Sell
878
-364
-29% -$9.67K ﹤0.01% 2199
2018
Q4 		$32K Buy
1,242
+452
+57% +$13.2K ﹤0.01% 2099
2018
Q3 		$26K Buy
790
+480
+155% +$17.4K ﹤0.01% 2171
2018
Q2 		$11K Buy
+310
New +$9.09K ﹤0.01% 2257

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
TMC
Trellus Management Company Delray Beach, Florida $72.8M AUM 4.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Panagora Asset Management's SLNO Position: Q3 2019 in Review

Panagora Asset Management sold out of Soleno Therapeutics (SLNO) in Q3 2019, closing a stake of 363 shares — an estimated $15K sold.

Panagora Asset Management first reported a position in SLNO in Q2 2018 and held it in 5 quarters. The position peaked at $32K in Q4 2018. 18 funds tracked by Wall St. Rank hold SLNO as of Q3 2019.

  • Panagora Asset Management reported no remaining Soleno Therapeutics position as of Q3 2019 after selling out during the quarter.
  • Panagora Asset Management sold 363 Soleno Therapeutics shares in Q3 2019, an estimated $15K.
  • Panagora Asset Management first reported a position in Soleno Therapeutics in Q2 2018 and held it in 5 quarters.
  • Panagora Asset Management's Soleno Therapeutics position peaked at $32K in Q4 2018.
  • 18 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2019.

Based on Panagora Asset Management's 13F filing for Q3 2019, filed 12 Nov 2019.